Global Reach Health

April 6, 2021

New Dosing Regimen Approved for Erbitux

April 6, 2021 – The U.S. FDA has approved a new dosing regimen for Erbitux® (cetuximab), manufactured by ImClone. The drug may now be administered once every two weeks to treat